We evaluated the use of two tumour markers Cyfra 21.1 and tissue polypeptide antigen (TPA) for disease monitoring. Assessment of response to WHO criteria was compared to response assessment according to changes in the tumour marker levels. The criteria defined for marker response were a 65% decrease for a partial response and a 40% increase for progressive disease. When response evaluations with a positive lead time were included, 72% of 115 evaluations for Cyfra 21.1 and 59% of 107 evaluations for TPA yielded the same result. Most discordant evaluations were caused by those evaluations whereby the patient achieved a partial response according to the WHO criteria and had normalisation of the marker. Less cases with a positive lead time, more negative lead times, and more patients with progressive disease without an increase of the marker were seen with TPA compared to Cyfra 21.1. In conclusion, Cyfra 21.1 follows the changes in the turnout load better than TPA. Rising levels of both markers nearly always indicate disease progression, and such knowledge easily obtained may prevent the continuation of ineffective treatment.
INTRODUCTION
MANY PATIENTS with non-small cell lung cancer (NSCLC) present with advanced disease or will relapse after initial surgery and/or radiotherapy, and may become candidates for systemic treatment. The impact of chemotherapy on survival is, however, small and the benefit seems to be restricted to those patients who achieve an objective response to treatment [I] . Therefore, monitoring of treatment and early detection of those patients who progress during treatment is important to avoid continuation of unnecessary toxic treatment.
The evaluation of response to chemotherapy may sometimes be difficult, especially in those cases where the bulk of disease is represented by non-evaluable lesions, and may require expensive and time-consuming investigations, such as computed tomography and magnetic resonance imaging.
In a recent study, we reported our first results with the tumour marker, Cyfra 2 1.1, the antibody to which detects a fragment of cytokeratin 19 in serum [2] . We showed that the sensitivity to Correspondence to A. van der Gaast.
A. van der Gaast, T.C. Kok and T.A.W. Splinter Cyfra 21.1 in 212 patients with NSCLC, predominantly stage 3a-b and 4, was 40%. In addition, the sensitivity to another cytokeratin marker, tissue polypeptide antigen (TPA), tested in the same group of patients was also 40%. The sensitivities for both markers were higher in patients with stage 4 disease than in patients with stage 3 disease. Median levels of Cyfra 2 1.1 were significantly higher in patients with squamous cell carcinomas compared with the median levels found in patients with adenocarcinomas or large cell undifferentiated carcinomas. Furthermore, we demonstrated that Cyfra 21.1 was a useful marker for monitoring chemotherapy in patients with squamous cell carcinoma.
In the present study, we extended the monitoring data to include patients with adenocarcinoma and large cell undifferentiated carcinoma of the lung, and compared these results with those obtained with TPA. The TPA assay detects cytokeratins 8,18 and 19 [3] . We have previously reported a high intermarker correlation between Cyfra 21.1 and TPA at diagnosis [2] , and so investigated which one of these two markers would be the more accurate for disease monitoring.
Patients

PATIENTS AND METHODS
The initial cohort included 212 patients with histologically proven inoperable NSCLC, from whom serum samples were collected at diagnosis and during treatment for those who received chemotherapy. Fro.m this group of patients, 50 fulfilled the following eligibility criteria: (1) treated with chemotherapy; (2) a sufficient number of marker determinations during chemotherapy i.e. at least three se:rum samples; (3) evaluable lesions; and (4) an elevated level of Cyfra 2 1.1 or TPA at the start of treatment.
All patients were staged according to the guidelines of the American Joint Committee on Cancer [4] . Nodal status was confirmed histologically or cytologically by mediastinoscopy, mediastinotomy or thoracotomy for those patients with stage IIIa disease. Response to chemotherapy was assessed, in general, after every two courses, according to standard WHO criteria [5] without knowledge of any tumour marker level. The following response criteria for tumour markers were used: complete response, normalisation of an elevated marker for at least 1 month; partial response, decrease of 65% or more of an elevated marker for at least 1 month; stable disease, less than 65% decrease or less than 40% increase of an elevated marker; progressive disease, more than 40% increase of an elevated marker level or a rise from below to above the cut-off level. These criteria are based on the assumption that the tumour marker levels correspond to three-dimensional measurements of the total body tumour load. A 50% decrease of a bidimensional measurement (WHO criteria) roughly corresponds to a 65% decrease of a volumetric measurement, and a 25% increase of a bidimensional measurement corresponds to a 40% increase of a volumetric measurement. When both methods of evaluation yielded the same result at ,the same time, the evaluation was called concordant.
Marker assessments
Serum Cyfra 2 1.1 assay vallues were determined using a solidphase double determinant immunoradiometric assay (Centocor Diagnostics, Malvern, Pennsylvania, U.S.A.). This assay utilises two monoclonal antibodies (KS 19.1 and BM 19.21 ) reactive with different epitopes expressed by cytokeratin 19 fragments. KS 19.1 is coated on the solid phase and the BM 19.21 antibody, radiolabelled with iodine 12 5, is used as a tracer. For the Cyfra 2 1.1 assay, the coefficients for interassay variation were between 7.0 and 11.9%. TPA was measured with a commercial kit (Protigen RIA Sangtec Medical Co, Bromma, Sweden) according to the manufacturer's instructions.
Cut-off values used in this study were 3.3 ng/rnl for Cyfra 21.1 and 170 U/l for TPA. These cut-off values correspond to a %% specificity for both markers determined in 546 patients with non-malignant lung diseases [6] .
RlESULTS
The patient characteristics of the 50 eligible patients are listed in Table 1 .37 of the 50 patie:nts had elevated levels of both Cyfra 21.1 andTPA.
A scattergram of the pretreatment levels of both markers is shown in Figure 1 , demonstrating the high correlation between the two markersinpretreatment samples (r = 0.81,P < 0.001).
Disease monitoring with Cyfi~! 2 1.1 Of the 46 patients with an (elevated Cyfra 2 1 . 1 , 115 evaluations for response were performed. The concordance between the results of the clinical evaluations according to WHO criteria and the changes in the marker iaccording to the earlier mentioned criteria was 63%.
Twenty-four of the 42 discordant evaluations were caused by patients with a clinical partial response and a decrease of the marker below the cut-off level (Table 2 ). Ten discordant evaluations could be explained by a positive lead time of the marker, i.e. the change in the tumour marker preceded the results obtained by the clinical evaluation by l-2 months. On 9 of these 10 occasions, the marker indicated disease progression while the clinical response was stable disease; the tenth event occurred in a patient who had normalisation of the marker and stable disease, which later changed into a partial response. A negative lead time was observed once in a patient with progressive disease, while the tumour marker met the criteria for progressive disease only 4 weeks later. Five evaluations yielded stable disease clinically and a partial response according to the marker level on one occasion and a complete response indicated by the marker on four occasions. In most of these, tumour regression was observed, but was not sufficient to reach the A. van der Gaast et al. criteria for partial response. One patient had an increase in the marker level when clinical progression was documented, but this was not enough to meet the criteria set for marker progression. The last discordant evaluation was in a patient who had progressive disease according to the marker, but stable disease according to the WHO criteria. This patient was subsequently treated with radiotherapy so that the possibility of a positive lead time of the marker could not be assessed. A summary of the discordant evaluations of Cyfra 21.1 is given in Table 2 .
Disease monitoring with TPA
Of 41 patients with an elevated TPA, 107 evaluations for response were performed. The concordance between the results of the clinical evaluations according to WHO criteria and the changes in the marker was 54%.
Five of the 49 discordant evaluations were due to a positive lead time of the marker, whereby the marker indicated disease progression while the clinical response was stable disease (Table  3) . A negative lead time was seen four times in patients with clinical progressive disease and progressive disease according to the tumour marker criteria l-2 months later. In 5 patients with disease progression according to the WHO criteria, the marker levels remained stable. A reduction in the TPA levels below the cut-off level was seen on 23 occasions when the clinical response was a partial response and on 11 occasions when the clinical response was stable disease. In one patient with a partial response, the marker level indicated stable disease. A summary of the discordant evaluations of TPA is given in Table 3 .
In Figure 2 , an example is shown of Cyfra 21.1 and TPA levels during treatment, whereby the course of both markers is identical. An example of a patient with progressive disease and increasing Cyfra 2 1.1 levels, but a stable level of TPA is shown in Figure 3 . 
DISCUSSION
The most common application of serum tumour markers is disease monitoring, and tumour markers such as alpha-fetoprotein, S-chorionic gonadotropin, prostate specific antigen, CA-15.3 and C-125 have become invaluable in the management of patients with testicular, prostate, breast and ovarian cancer [7] .
The aim of the present study was to investigate whether Cyfra 2 1.1 and TPA are useful serum tumour markers for disease monitoring in patients with NSCLC during chemotherapy.
Although a number of studies have investigated the role of TPA for disease monitoring in NSCLC patients, in virtually none have criteria been defmed for marker response nor been correlated with response assessments according to standard WHO criteria. Monitoring data for Cyfra 21.1 are scarce. Since both markers measure cytokeratins, cytokeratin 19 for Cyfra 21.1 and cytokeratin 8, 18 and 19 for TPA, we were also interested in a comparison between these two markers. Moreover, it has also been claimed that the serum levels of TPA are indicative of the proliferation activity of a tumour [8] .
Using strictly defined criteria for a marker response (i.e. a 46% increase of the marker level for disease progression and a 65% decrease in the marker level for a partial response) and considering evaluations with a positive lead time as concordant, we found a concordance between response evaluation according
